Joseph Talamo
Chief Financial OfficerMr. Joseph Talamo, C.P.A. M.B.A. also known as Joe, serves as Chief Financial officer of Intensity Therapeutics, Inc. since December 11, 2023. He serves as Chief Financial Officer at HiberCell, Inc. since from August 2020 until November 2023. He had been the Chief Financial Officer of Caladrius Biosciences, Inc. since October 5, 2015 until August 21, 2020 and served as its Senior Vice President since October 2015 until August 21, 2020. Mr. Talamo served as Vice President, Corporate Controller and Chief Accounting Officer at Caladrius Biosciences, Inc. since June 2011 until October 2015. He served various senior positions at OSI Pharmaceuticals, Inc. and served as its Vice President and Corporate Controller. While at OSI from 1996 to 2010, Mr. Talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva(R), OSI's targeted therapy approved for the treatment of patients with non-small cell lung cancer and pancreatic cancer. Prior to OSI, Mr. Talamo worked at Bristol-Myers Squibb from 1995 to 1996 in the Financial Reporting and Consolidations Group and at KPMG from 1993 to 1995 in the Health Care and Life Sciences Audit Group. Mr. Talamo also served as Treasurer of OSI Pharmaceuticals Foundation from 2008 to 2010. Mr. Talamo received a Bachelor of Business Administration in Accounting from Hofstra University in 1991 and a Master of Business Administration in Finance from Hofstra University in 1999. Mr. Talamo is a certified public accountant in the State of New York.
Positions
- Company NameIntensity Therapeutics, Inc.Stock CodeINTSPositionChief Financial OfficerColleagues
- LHLewis H. BenderFounder, President, CEO & Chairman of the Board
- JWJohn WesolowskiPrincipal Accounting Officer & Controller
- JMJames M. AhlersExecutive Vice President of Corporate Finance
- ELEmer LeahyIndependent Director
- MAMark A. GoldbergIndependent Director
- DJDaniel J. DonovanIndependent Director
- RLRiccardo LencioniMember of Scientific Advisory Board
